Strand Life Sciences, a prominent player in genomics and bioinformatics, has introduced a blood-based screening tool aimed at the precocious identification of various cancers. CancerSpot leverages cutting-edge methylation profiling techniques that are internationally recognized to detect DNA fragments of cancerous tumors.
This test requires just a simple blood sample and employs a proprietary genome sequencing and analysis strategy to discern DNA methylation patterns of cancer present in the bloodstream, as announced by Strand Life Sciences, a branch of Reliance Industries.
“Cancer is increasingly becoming a significant contributor to illness and death in India, imposing considerable financial, social, and emotional stress on patients, their families, and communities,” commented Isha Ambani Piramal, who serves on the Board of Reliance Industries.
In support, she expressed, “Hence, Strand’s innovative early cancer detection test aligns with our goal of providing transformative healthcare solutions.”
The company pledges to harness the potential of genomics to advance healthcare and enhance well-being, impacting lives both in India and globally. “For 24 years, Strand has been at the forefront of genomic advancements. This new development marks another milestone for India arising from a comprehensive, multi-year research endeavor,” stated Ramesh Hariharan, CEO and co-founder of Strand Life Sciences.